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Decrease in Growth Hormone and Insulin-like Growth Factor (IGF) - 1 
Release and Amelioration of Acromegaly Features after Rosiglitazone 
Treatment of Type 2 Diabetes Mellitus in a Patient with Acromegaly
A 28-year-old woman with clinical features of acromegaly and 
diabetes mellitus was admitted to our Reference Center for Clini-
cal Neuroendocrinology and Pituitary Diseases at Sisters of Mercy 
University Hospital, Zagreb, Croatia. Magnetic resonance scan of 
the brain showed pituitary macroadenoma. After transsphenoidal 
resection, histological analysis confirmed it was a growth hormone 
(GH)-secreting pituitary adenoma. The tumor could not be com-
pletely removed, but the hormonal status normalized. A month after 
the surgery, octreotide was introduced because of a further increase 
in GH and insulin-like growth factor-I (IGF-I), but discontinued 
after a week due to intolerance. Alternative treatment with oral anti-
diabetic agent, rosiglitazone, was introduced two weeks after octreo-
tide was discontinued, and the fasting blood glucose concentration 
decreased from 8.4 mmol/L before the treatment to 6.7 mmol/L 
after 90 days of treatment. The concentration of GH and IGF-I in 
the week before rosiglitazone was introduced was 5.96 ng/mL and 
990 ng/mL, respectively, and decreased to 2.92 ng/mL and 180.0 
ng/mL, respectively, after 90 days of treatment. There was also a 
pronounced improvement in acromegalic features. It is possible that 
rosiglitazone induced the decrease in GH and IGF-I concentrations 
and its role in the long-term medical therapy of patients with pitu-
itary tumors should be further investigated.
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Acromegaly is a disease characterized by excessive 
growth hormone (GH) secretion from pituitary 
adenomas, which in turns leads to overexpres-
sion of IGF-I, the main effector of GH action 
(1-3). Treatment of acromegaly is a therapeu-
tic challenge (4). In most of these GH-secreting 
pituitary tumors, dopamine agonists or soma-
tostatin analogues suppress the hypersecretion of 
GH and control tumor growth or induce tumor 
shrinkage (4,5). Nevertheless, a subset of patients 
with GH-secreting pituitary tumors do not re-
spond to or do not tolerate these drugs (5,6). Pi-
tuitary microsurgery is usually the treatment of 
first choice, but is not always successful in achiev-
ing early remission. It is also associated with a sig-
nificant incidence of late relapse. In spite of the 
combination of surgery, external x-ray therapy 
and medical therapy, many patients continue to 
have uncontrolled GH secretion and active dis-
ease (7). Excessive GH concentrations lead to 
insulin resistance in 80% of patients with acro-
megaly, with impaired glucose tolerance occur-
ring in approximately 40% and diabetes mellitus 
in 10%-20% (8). These parameters improve with 
treatment, and complete resolution of diabetes 
mellitus occurs in two-thirds of these patients af-
ter successful surgery (2,8).
Rosiglitazone has been widely used in clinical 
practice as an oral antidiabetic agent for the treat-
ment of diabetes mellitus and disturbed lipid me-
tabolism in patients with type 2 diabetes mellitus 
and obesity (9). It also improves insulin sensitiv-
ity and glucose homeostasis in patients with im-
paired glucose tolerance (10). Rosiglitazone be-
longs to the class of thiazolidinediones, a group 
of compounds with high affinity for a nuclear 
hormone receptor pituitary peroxisome prolif-
erator-activated receptor-gamma (PPAR-γ) (9). 
Activation of PPAR-γ is involved in adipocyte 
differentiation process (11), glucose metabolism 
(9), inhibition of inflammatory response (12), 
and anti-angiogenesis (13). Recently, abundant 
expression of this receptor was demostrated in 
human PRL- and GH-secreting and non-func-
tioning pituitary tumors, as well as inhibition 
of tumor growth and hormonal activity in vivo 
and in vitro by PPAR-γ ligands (14). Bogazzi et 
al (15) demonstrated that PPAR-γ is expressed 
in all human GH-secreting adenomas and con-
trolled GH transcription and secretion, as well 
as apoptosis and growth of GH-adenomas. In 
this case report, we describe the effects of rosigli-
tazone treatment of diabetes mellitus in a patient 
with acromegaly caused by a GH-secreting pitu-
itary tumor.
Case Report
A 28-year-old woman, presenting with head-
ache, bitemporal hemianopia, coarsening of the 
facial features and soft tissue, and swelling of the 
hands and feet was admitted to our Reference 
Center. These symptoms had been developing 
for four years before she was admitted. She was 
never treated before and was referred to the cen-
ter by her general practitioner. The patient un-
derwent physical examination, laboratory test-
ing, and magnetic resonance imaging (MRI) of 
the head. Blood pressure was normal (120/80 
mm Hg) and body mass index was 24.4 kg/m2. 
Radioimmunoassay showed increased serum 
GH concentration of 28.31 ng/mL (normal val-
ues, <5 ng/mL). The concentration of IGF-I, de-
termined with immunoradiometric assay, was 
also increased to >1300 ng/mL (normal range, 
115-420 ng/mL) and there was a failure of ade-
quate GH suppression after oral administration 
of 75 mg of glucose (appropriate suppression, af-
ter glucose load GH<1 ng/mL). Fasting plasma 
glucose was 8.4 mmol/L, postprandial plasma 
glucose 9.1 mmol/L, and HbA1c 7.6%, cofirm-
ing the diagnosis of type 2 diabetes mellitus. Re-
nal and hepatic functions were normal, as well as 
electrolytes. The concentrations of thyroxin, tri-
iodotothyronine, thyroid-stimulating hormone, 
adrenocorticotropic hormone (ACTH), cortisol, 
and prolactine (PRL) were normal, but the levels 
of gonadotropins were extremely low: luteinizing 
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hormone (LH)<1.0 IJ/L (normal range, 1.9-8.0 
IJ/L), follicle-stimulating hormone (FSH) 1.2 
IJ/L (normal range, 2.4-9.3 IJ/L) with resulting 
low levels of peripheral sex hormones estradiol 
76 pmol/L (normal range, 92-367 pmol/L), pro-
gesterone <0.3 nmol/L (normal range, 0.3-3.8 
nmol/L).
The initial MRI of the pituitary region, per-
formed on a Siemens 1T instrument (Siemens, 
Erlangen, Germany), with 2-mm thick sections, 
showed a 40 × 30 × 40 mm macroadenoma of 
the pituitary gland (Figure 1A). The patient un-
derwent transsphenoidal surgery, but the tumor 
could not be completely removed (Figure 1B). 
The residual tumor mass of 16 × 19 × 12 mm 
was located in the left cavernous sinus, adjacent 
to the cavernous segment of the internal carotid 
artery. Postoperative histological analysis of the 
resected tumor tissue confirmed the diagnosis 
of GH-secreting pituitary adenoma. A week af-
ter the operation, the patient’s hormonal status 
was normal, with a decrease in the concentration 
of growth hormone to 4.20 ng/mL and IGF-I to 
486 ng/mL. Since the concentrations of growth 
hormone and IGF-I increased again to 6.15 ng/
mL and 637 ng/mL, respectively, one month af-
ter the operation, octreotide treatment was in-
troduced.
Treatment with octreotide (Sandostatin, 
Sandoz Pharma Ltd, Basel, Switzerland) in a sub-
cutaneous daily dose of 0.5 mg, which was com-
menced 30 days after the surgery, had to be dis-
continued after one week due to intolerance. 
The evaluation of patient’s hormonal status two 
weeks after the discontinuation of octreotide 
treatment revealed increased concentrations of 
both growth hormone (5.96 ng/mL) and IGF-
I (990 ng/mL). In addition, the patient com-
plained of visual disturbances and headaches, 
while the swelling of the lips and enlargement of 
the hands and feet were still present. Treatment 
with oral PPAR-γ agonist rosiglitazone (Avandia, 
Glaxo Wellcome Production, Mayenne, France) 
in a dose of 8 mg once per day was introduced for 
the treatment of diabetes mellitus, which was still 
present in the patient, two weeks after octreotide 
was discontinued. The patient tolerated rosigli-
tazone well and was discharged from the hospi-
tal, but remained under regular medical supervi-
sion.
Figure 1. Magnetic resonance imaging (MRI) brain scan in the 28-
year-old patient with acromegaly. (A) Preoperative MRI coronal scans 
revealed a tumor mass in the sellar and parasellar region. The largest 
size of tumor mass at the baseline was 40 × 30 × 40 mm. (B) Coronal 
MRI brain scans after transsphenoidal surgery of pituitary adenoma 
showed residual tumor mass. The largest size of tumor mass was 
16 × 19 × 18 mm.
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Plasma glucose, GH, and IGF-I were deter-
mined before and on the day 1, 2, 7, 30, 60, and 
90 of the rosiglitazone treatment. During the 90 
days of rosiglitazone treatment, fasting plasma 
glucose concentration ranged between 8.4 and 
6.7 mmol/L (normal range, 4.1-6.1 mmol/L), 
and postprandial plasma glucose was 8.2 mmol/
L (normal range, <7.8 mmol/L). Plasma GH 
and IGF-I values in the week before the surgery 
were 5.96 ng/mL and 990 ng/mL, respectively, 
and decreased to 2.92 ng/mL and 180 ng/mL, 
respectively , after 90 days of rosiglitazone treat-
ment (Figure 2). There was also a noticeable im-
provement in acromegalic features, the headache 
and swellings resolved, and the patient made a 
good recovery.
Discussion
A 28-year-old woman with residual pituitary tu-
mor, clinical features of acromegaly and diabe-
tes mellitus was treated with PPAR-γ agonist, 
rosiglitazon, to improve blood glucose level. She 
did not tolerate octreotide treatment so it was 
discontinued. Blood glucose levels normalized 
in our patient over the 90 days of rosiglitazone 
treatment. The octreotide treatment was discon-
tinued and blood glucose levels normalized over 
the 90 days of rosiglitazone treatment. Serum 
GH and IGF-I concentrations also decreased to 
normal values, and acromegalic features remark-
ably improved.
The reduction of the tumor mass as well as 
postoperative decrease in growth hormone and 
IGF-I blood concentrations was the result of sur-
gical removal of the tumor. However, in our pa-
tient, IGF-I levels steadily rose during the 30 days 
of postoperative period. Octreotide therapy that 
lasted 7 days could not significantly influence 
the reduction of the residual tumor mass due to 
short duration of administration. Also, octreo-
tide could influence the secretion of growth hor-
mone and IGF-I only during the 7 days of admin-
istration. Given the short half-life of Sandostatin 
(t˝ = 100 minutes), longer influence on the secre-
tion of the hormones could not be expected af-
ter the treatment was discontinued. Therefore, it 
seemed plausible to conclude that the further de-
crease in hormone concentrations was the result 
of rosiglitazone treatment. Finally, it is possible 
that the long term effectiveness of rosiglitazone 
on hormone secretion might also be due to the 
induction of G0-G1 cell-cycle arrest and apopto-
sis by PPAR-γ agonist, as shown in secreting and 
non-functioning pituitary adenomas (14).
Rosiglitazone is indicated primarily for the 
treatment of diabetes mellitus and has only re-
cently emerged as a potential therapy for pitu-
itary tumors (14). Heaney et al (14) found that 
PPAR-γ was abundantly present in PRL-, GH-, 
and LH-secreting, as well as non-functioning pi-
tuitary tumors and that exposure of the tumor 
tissue to rosiglitazone inhibited both the pro-
liferation of tumor cells in vitro and in vivo and 
secretion of PRL-, GH-, and LH in vivo. Thus, 
PPAR-γ could become a novel molecular tar-
get in the treatment of patients with non-func-
tioning and hormone-secreting pituitary tumors 
that are unresponsive to current dopamine ago-
Figure 2. Decrease in growth hormone (GH) (A) and insulin-like 
growth factor I (IGF-I) (B) secretion in the patient with acromegaly 
during 90 days of rosiglitazone treatment after hypophyseal surgery.
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nist and/or somatostatin analogues (16). There 
are few reports on the effects of rosiglitazone in 
the treatment of patients with pituitary tumor-
related conditions. A recent report on the results 
of rosiglitazone treatment in two patients with 
Cushing disease showed that the drug, adminis-
tered for a few weeks at a dose of 8 mg/d, signifi-
cantly decreased urinary levels of free cortisol and 
led to a modest clinical improvement in both cas-
es (17). On the other hand, rosiglitazone showed 
no effects in lowering ACTH levels in patients 
with Nelson syndrome (18).
The primary indication for rosiglitazone 
treatment in our patient was diabetes mellitus. 
However, during the postoperative follow-up of 
the patient’s hormonal status, we observed an 
unexpected decrease in the GH and IGF-I secre-
tion and remarkable improvement in acrome-
galic features. There is a reasonable assumption 
that rosiglitazone was responsible for the nor-
malization of GH and IGH-I secretion, in addi-
tion to blood glucose concentration. Since this is 
the first report on the outcome of rosiglitazone 
treatment in a patient with GH-secreting pitu-
itary tumor and consequent acromegaly and di-
abetes mellitus, further research is needed to es-
tablish and confirm the possible role of this drug 
in the treatment of patients with pituitary tu-
mors. Since we were only able to use the max-
imum dose licensed for use in diabetes (8 mg), 
further carefully designed studies of both dose 
and duration are required to confirm and de-
fine its possible role.
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